Results 141 to 150 of about 87,212 (241)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate changes in dietary intake following liraglutide treatment, compared to dietitian‐supported caloric restriction and a weight‐neutral control, and to assess dietary intake against nutrition recommendations. Materials and Methods Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day ...
Kelli M. Richardson   +4 more
wiley   +1 more source

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Tirzepatide and semaglutide demonstrated clinically meaningful weight reduction in people with obesity or overweight and type 2 diabetes (T2D) in SURMOUNT‐2 and STEP 2 clinical trials, respectively. In the absence of head‐to‐head trials, this study compared the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect
Emily R. Hankosky   +7 more
wiley   +1 more source

Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To determine the adherence rate in users of each class of glucose‐lowering medication and identify the key socio‐demographic factors influencing adherence. Methods The 45 and Up Study is an ongoing cohort study of residents aged ≥45 years in New South Wales, Australia.
Crystal M. Y. Lee   +3 more
wiley   +1 more source

Relation Between Glycated Hemoglobin Level and Hearing Loss in Type 2 Diabetic Patients. [PDF]

open access: yesJ Int Adv Otol
ElSherif M   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy